Free Trial
NASDAQ:MRSN

Mersana Therapeutics Q2 2023 Earnings Report

Mersana Therapeutics logo
$7.32 -0.34 (-4.44%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$7.33 +0.01 (+0.19%)
As of 08/29/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics EPS Results

Actual EPS
-$11.75
Consensus EPS
-$11.00
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A

Mersana Therapeutics Revenue Results

Actual Revenue
$10.70 million
Expected Revenue
$12.93 million
Beat/Miss
Missed by -$2.23 million
YoY Revenue Growth
+148.80%

Mersana Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Mersana Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Mersana Therapeutics Earnings Headlines

BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
See More Mersana Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mersana Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mersana Therapeutics and other key companies, straight to your email.

About Mersana Therapeutics

Mersana Therapeutics (NASDAQ:MRSN), a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

View Mersana Therapeutics Profile

More Earnings Resources from MarketBeat